<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32021">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689804</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP1857</org_study_id>
    <nct_id>NCT02689804</nct_id>
  </id_info>
  <brief_title>EC PK in Women With Normal and Obese BMI</brief_title>
  <official_title>Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A well-designed pharmacokinetics (PK) study may identify the physiologic basis for observed
      differences in levonorgestrel emergency contraception (LNG-EC) and ulipristal acetate
      emergency contraception (UPA-EC) failure rates in women with normal and obese BMI. The
      investigators propose a study to compare serum LNG and UPA levels after administration of a
      single-dose of LNG-EC or UPA-EC. The investigators hypothesize that there will be no
      difference in PK parameters between women with normal BMI and obese women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women will present to the division research office, at which time a history and
      physical exam will be completed. Each participant's BMI will be confirmed and she will be
      assigned to one of two BMI groups (18.5-24.9 versus 30-39.9). At the conclusion of the
      enrollment visit, the research coordinator will randomize each woman to receive a
      single-dose pill of either levonorgestrel 1.5mg (like Plan B One-Step® or its generic
      formulations) or ulipristal acetate 30mg (ellaOne®) on two separate occasions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time 0 to 24 hours of serum LNG concentration</measure>
    <time_frame>9 months</time_frame>
    <description>(AUC0-24h) compared in women with normal versus obese BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time 0 to 24 hours of serum UPA concentration</measure>
    <time_frame>9 months</time_frame>
    <description>(AUC0-24h) compared in women with normal versus obese BMI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of serum LNG</measure>
    <time_frame>9 months</time_frame>
    <description>(t1/2) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of serum UPA</measure>
    <time_frame>9 months</time_frame>
    <description>(t1/2) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of serum LNG</measure>
    <time_frame>9 months</time_frame>
    <description>(Vd) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of serum UPA</measure>
    <time_frame>9 months</time_frame>
    <description>(Vd) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of serum LNG</measure>
    <time_frame>9 months</time_frame>
    <description>(Cl) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of serum UPA</measure>
    <time_frame>9 months</time_frame>
    <description>(Cl) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to infinity of serum LNG concentration</measure>
    <time_frame>9 months</time_frame>
    <description>(AUC0-∞) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to infinity of serum UPA concentration</measure>
    <time_frame>9 months</time_frame>
    <description>(AUC0-∞) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of serum LNG</measure>
    <time_frame>9 months</time_frame>
    <description>(Cmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of serum UPA</measure>
    <time_frame>9 months</time_frame>
    <description>(Cmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of serum LNG</measure>
    <time_frame>9 months</time_frame>
    <description>(Tmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of serum UPA</measure>
    <time_frame>9 months</time_frame>
    <description>(Tmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>16 women with normal BMI and 16 women with obese BMI receive a single-dose of levonorgestrel 1.5mg by mouth. Serial blood collections are collected over a 48-hour period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulipristal acetate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>16 women with normal BMI and 16 women with obese BMI receive a single-dose of ulipristal acetate 30mg by mouth. Serial blood collections are collected over a 48-hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel 1.5mg</intervention_name>
    <description>FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg</description>
    <arm_group_label>Levonorgestrel</arm_group_label>
    <other_name>Next Choice One Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal acetate 30mg</intervention_name>
    <description>FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg</description>
    <arm_group_label>Ulipristal acetate</arm_group_label>
    <other_name>ellaOne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-45 years

          -  English-speaking

          -  BMI 18.5-24.9 or BMI 30.0-39.9

          -  Regular menstrual cycles

          -  No use of medroxyprogesterone acetate at least 6 months prior to study enrollment,
             unless resumption of two menstrual cycles

          -  No use of levonorgestrel intrauterine system (levonorgestrel-IUS), etonogestrel
             implant or combined hormonal contraception at least one month prior to the study and
             resumption of one menstrual cycle

          -  Women who are postpartum or post-abortion will be included if they have had at least
             one menstrual cycle since their last pregnancy

        Exclusion Criteria:

          -  Prior allergic reaction to LNG-EC or UPA-EC

          -  Use of hormonal emergency contraception within the past month

          -  Women who are currently pregnant or who are currently breastfeeding

          -  History of cancer other than non-melanoma skin cancer

          -  Medical or surgical conditions or conditions requiring therapies known to impact sex
             steroid production or metabolism

               -  Use of HAART therapy for management of HIV infection

               -  Concomitant use of CYP3A4 inducers like rifampin, barbiturates, carbamazepine,
                  lamotrigine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St.
                  John's Wort and topiramate

          -  Current participation in any other trial of an investigational medicine or device in
             the three months leading up to this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn L Westhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Division of Family Planning and Preventive Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piyapa Praditpan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical instructor, Division of Family Planning and Preventive Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, Gainer E, Ulmann A. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011 Oct;84(4):363-7. doi: 10.1016/j.contraception.2011.02.009. Epub 2011 Apr 2.</citation>
    <PMID>21920190</PMID>
  </reference>
  <reference>
    <citation>Kapp N, Abitbol JL, Mathé H, Scherrer B, Guillard H, Gainer E, Ulmann A. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception. 2015 Feb;91(2):97-104. doi: 10.1016/j.contraception.2014.11.001. Epub 2014 Nov 8.</citation>
    <PMID>25528415</PMID>
  </reference>
  <reference>
    <citation>Gemzell-Danielsson K, Kardos L, von Hertzen H. Impact of bodyweight/body mass index on the effectiveness of emergency contraception with levonorgestrel: a pooled-analysis of three randomized controlled trials. Curr Med Res Opin. 2015 Dec;31(12):2241-8. doi: 10.1185/03007995.2015.1094455. Epub 2015 Oct 27.</citation>
    <PMID>26368848</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 28, 2016</lastchanged_date>
  <firstreceived_date>February 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Carolyn L. Westhoff</investigator_full_name>
    <investigator_title>Director, Division of Family Planning and Preventive Services</investigator_title>
  </responsible_party>
  <keyword>Emergency contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Postcoital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
